La catena delle opzioni mostra i dati chiave delle opzioni azionarie di BTC Digital a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per BTC Digital..

BTC Digital (NASDAQ:BTCT) Azioni, Catena delle Opzioni

BTC Digital

Meten Holding Gr

BTC Digital Ltd is a crypto asset technology company based in the U.S. with a focus on bitcoin mining. The company also generates revenue through mining machine resale and rental business operations.

BTC Digital Ltd

Bitcoin - TrueUSD

BTC Digital Ltd Warrants (31/03/2025)

TELUS Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIXT#NYSE">TIXT</a>) affirms FY2025 Adj EPS guidance from $0.32 to $0.32 vs $0.32 analyst estimate..

News

Guidance

TIXT

TELUS Intl Affirms FY2025 Adj EPS Guidance of $0.32 vs $0.32 Est

HC Wainwright &amp; Co. analyst Heiko Ihle maintains United States Antimony (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAMY#AMEX">UAMY</a>) with a Buy and raises the price target from $2.6 to $4.5.

Price Target

Analyst Ratings

UAMY

HC Wainwright & Co. Maintains Buy on United States Antimony, Raises Price Target to $4.5

TELUS Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIXT#NYSE">TIXT</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.05 by 20 percent. This is a 72.73 percent decrease over earnings of $0.22 per share from the same period last year. The company reported quarterly sales of $670.00 million which beat the analyst consensus estimate of $653.24 million by 2.57 percent. This is a 1.98 percent increase over sales of $657.00 million the same period last year.

Earnings

Earnings Beats

TELUS Intl Q1 Adj. EPS $0.06 Beats $0.05 Estimate, Sales $670.00M Beat $653.24M Estimate

Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) with a Buy and lowers the price target from $55 to $35.

Chardan Capital Maintains Buy on Silence Therapeutics, Lowers Price Target to $35

Docebo (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#TSX">DCBO</a>) sees FY2025 sales of $236.455 million-$238.624 million vs $241.08 million analyst estimate.

TSX:DCBO

Docebo Sees FY2025 Sales $236.455M-$238.624M vs $241.08M Est

HC Wainwright &amp; Co. analyst Heiko Ihle maintains First Majestic Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) with a Buy and raises the price target from $11 to $11.5.

HC Wainwright & Co. Maintains Buy on First Majestic Silver, Raises Price Target to $11.5

Chardan Capital analyst Daniil Gataulin maintains Oculis Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCS#NASDAQ">OCS</a>) with a Buy and raises the price target from $28 to $33.

Chardan Capital Maintains Buy on Oculis Holding, Raises Price Target to $33

Docebo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) lowers FY2025 sales outlook from $240.79 million-$242.96 million to $236.46 million-$238.62 million vs $241.54 million estimate.

DCBO

Docebo Lowers FY2025 Sales Guidance from $240.79M-$242.96M to $236.46M-$238.62M vs $241.54M Est

Docebo (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#TSX">DCBO</a>) sees Q2 sales of $59.000 million-$59.200 million vs $59.10 million analyst estimate.

Docebo Sees Q2 Sales $59.000M-$59.200M vs $59.10M Est

Canaccord Genuity analyst Joseph Vafi maintains Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Buy and maintains $400 price target.

COIN

Canaccord Genuity Maintains Buy on Coinbase Global, Maintains $400 Price Target

Canaccord Genuity analyst Joseph Vafi maintains Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy and maintains $17 price target.

Core Scientific, Inc. - Class A Common Stock

CORZ

Canaccord Genuity Maintains Buy on Core Scientific, Maintains $17 Price Target

Algonquin Power (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AQN#TSX">AQN</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.10 by 40 percent. This is unchanged from the same period last year. The company reported quarterly sales of $692.40 million which beat the analyst consensus estimate of $652.63 million by 6.09 percent. This is a 6.06 percent decrease over sales of $737.10 million the same period last year.

TSX:AQN

Algonquin Power Q1 Adj. EPS $0.14 Beats $0.10 Estimate, Sales $692.40M Beat $652.63M Estimate

Melinda French Gates has endorsed the Gates Foundation&#8217;s decision to allocate its entire $200 billion endowment to global health by 2045.
What Happened: French Gates, in her interview with Fortune, <a href="https://fortune.com/2025/05/08/melinda-french-gates-interview-gates-foundation-impact-gavi/">applauded </a>the move, calling it &#8220;fantastic&#8221;. She emphasized that the foundation&#8217;s resources were always meant to be returned to society. 
French Gates highlighted&nbsp;that only 2% of philanthropy&nbsp;is directed towards organizations working on gender issues. She reiterated her commitment to bridging this gap by utilizing her resources. Last year, she pledged $1 billion&nbsp;to support organizations and individuals&nbsp;promoting gender equality and empowering women. This announcement comes at a time when U.S. investments in gender-focused initiatives in Africa are facing hurdles, partly due to President Trump's rhetoric against diversity, equity, and inclusion (DEI) efforts.
"I'm ready to set more of an agenda here in the United States," asserted French Gates.
Gates expressed disappointment with the cuts in USAID and stated that philanthropy by billionaires can never fill in the gap. &#8220;You can never fill the gap if the public sector pulls back. You just can't.&#8221;
She also stressed the importance of giving back, especially for the wealthiest. According to her, U.S. billionaires, who have benefited from the country&#8217;s infrastructure and health sector, have a moral obligation to give back to society.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/events/25/04/44971154/trump-fails-to-impress-americas-young-shows-poll-as-they-still-favor-biden-only-15-think-us-on-right-track" target="_blank" rel="noreferrer noopener">Trump Fails To Impress America&#8217;s Young, Shows Poll As They Still Favor Biden — Only 15% Think US On Right Track &#8211; Benzinga</a>
Why It Matters: French Gates&#8217; commitment to global health and gender equality is not new. Earlier this month, she expressed concerns over the<a href="https://www.benzinga.com/markets/25/05/45186089/melinda-french-gates-takes-aim-at-elon-musks-doge-cuts-highlights-importance-of-philanthropy-and-government"> cuts made</a> by Elon Musk and the Department of Government Efficiency (DOGE) during President Donald Trump&#8217;s tenure. She emphasized the importance of government funding in expanding philanthropic efforts and warned about the potential devastating impacts of cuts to programs like USAID.
Her commitment to gender equality <a href="https://www.benzinga.com/tech/25/05/45162723/bill-gates-daughter-phoebe-says-mom-melinda-gave-tough-love-advice-after-investors-questioned-motherhood-plans-get-up-or-get-out-the-game">was also</a> evident when she gave practical advice to her daughter, Phoebe Gates, who faced questions from potential investors about future motherhood.
Moreover, her ex-spouse,&nbsp;Bill Gates, co-founder of&nbsp;Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), has also <a href="https://www.benzinga.com/markets/25/05/45286464/bill-gates-commits-99-of-his-remaining-fortune-to-gates-foundation-set-to-wind-down-in-20-years-somebody-should-give-more-money-than-i-did">pledged to donate</a> 99% of his remaining fortune to the Gates Foundation. This move further solidifies the Gates Foundation&#8217;s commitment to global health and philanthropy.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/global/25/05/45308582/pope-leo-xiv-didnt-spare-trump-administration-criticism-on-social-media-now-the-president-says-hes-excited-and-looking-forward-to-meeting-the-first-americ" target="_blank" rel="noreferrer noopener">Pope Leo XIV Didn&#8217;t Spare Trump Administration Criticism On Social Media — Now The President Says He&#8217;s &#8216;Excited&#8217; And Looking Forward To Meeting The First American Catholic Pontiff &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors

Equities

Markets

General

MSFT

Melinda French Gates Calls $200 Billion Gates Foundation Endowment For Global Health 'Fantastic,' Pledges Personal Funds For Gender Equality: '...Ready To Set More Of An Agenda Here In The United States'

Needham analyst Quinn Bolton reiterates Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and maintains $66 price target.

Reiteration

MCHP

Needham Reiterates Buy on Microchip Technology, Maintains $66 Price Target

Docebo (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#TSX">DCBO</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.22 by 22.73 percent. This is a 17.39 percent increase over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $57.30 million which beat the analyst consensus estimate of $57.10 million by 0.34 percent. This is a 11.46 percent increase over sales of $51.40 million the same period last year.

Docebo Q1 Adj. EPS $0.27 Beats $0.22 Estimate, Sales $57.30M Beat $57.10M Estimate

Canaccord Genuity analyst Joseph Vafi maintains Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) with a Buy and raises the price target from $130 to $179.

DAVE

Canaccord Genuity Maintains Buy on Dave, Raises Price Target to $179

Docebo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) sees Q2 sales of $59.000 million-$59.200 million vs $59.05 million analyst estimate.

Docebo Sees Q2 Sales $59.000M-$59.200M vs $59.05M Est

HC Wainwright &amp; Co. analyst Scott Buck maintains Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) with a Buy and lowers the price target from $7 to $5.

DPRO

HC Wainwright & Co. Maintains Buy on Draganfly, Lowers Price Target to $5

GRAVITY Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRVY#NASDAQ">GRVY</a>) reported quarterly earnings of $2.15 per share. This is a 25.09 percent decrease over earnings of $2.87 per share from the same period last year. The company reported $93.23 million in sales this quarter. This is a 4.85 percent increase over sales of $88.92 million the same period last year.

GRVY

GRAVITY Co Q1 EPS $2.15, Sales $93.23M Up From $88.92M YoY

Cineplex (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CGX#TSX">CGX</a>) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.34) by 70.59 percent. This is a 41.41 percent increase over losses of $(0.99) per share from the same period last year. The company reported quarterly sales of $264.28 million which missed the analyst consensus estimate of $270.99 million by 2.47 percent. This is a 10.34 percent decrease over sales of $294.76 million the same period last year.

Comments

BTC Digital

BTC Digital (BTCT) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO